Gasdermin family: a promising therapeutic target for asthma

As key regulators of inflammation and cell death, gasdermins (GSDMs) play a pivotal role in the pathogenesis of asthma. Through regulation via single nucleotide polymorphisms (SNPs), mediation of pyroptosis, and modulation of signaling pathways such as the MAVS-TBK1 pathway, GSDMs promote mucus hypersecretion, airway epithelial barrier dysfunction, and persistent inflammation, thereby exacerbating airway inflammation, airway remodeling, and pulmonary fibrosis. With the continuous expansion and deepening of research, GSDM-targeted inhibitors show great promise for precision therapy. Meanwhile, GSDM expression levels and specific SNPs may serve as potential biomarkers for the diagnosis and prognosis of asthma, providing novel strategies for asthma management.